Help is Here for Your Itchy Dog
Hear what dogs have tried to curb their allergic itch in this exciting episode of Let's Talk Itch! Find out how one treatment can provide the fast-acting relief they seek.
How Apoquel (oclacitinib tablet) is Different From Other Treatments
Apoquel Tablets have been prescribed for over 13 million dogs1 and are #1 in pet owner and vet satisfaction for oral medications for allergic dermatitis in dogs.2,3
- Antihistamines offer little or no benefit in treating flare-ups in a majority of dogs with allergic itch.4
- Apoquel can be used for short-term5 treatment or long-term6 management.
- Oatmeal baths, lotions, or over-the-counter topical medicines may provide some temporary relief but don’t get to the underlying cause of allergic itch.
IMPORTANT SAFETY INFORMATION: Do not use Apoquel or Apoquel Chewable in dogs less than 12 months of age or those with serious infections. Apoquel and Apoquel Chewable may increase the chances of developing serious infections, and may cause existing parasitic skin infestations or pre- existing cancers to get worse. Consider the risks and benefits of treatment in dogs with a history of recurrence of these conditions. New neoplastic conditions (benign and malignant) were observed in clinical studies and post- approval. Apoquel and Apoquel Chewable have not been tested in dogs receiving some medications including some commonly used to treat skin conditions such as corticosteroids and cyclosporines. Do not use in breeding, pregnant, or lactating dogs. Most common side effects are vomiting and diarrhea. Apoquel and Apoquel Chewable have been used safely with many common medications including parasiticides, antibiotics and vaccines. See full Apoquel Tablet and Apoquel Chewable Prescribing Information.
INDICATIONS: Control of pruritus (itching) associated with allergic dermatitis and control of atopic dermatitis in dogs at least 12 months of age.
*Based on survey data from veterinarians (n=251) and pet owners (n=552).
References:
- Data on file, ZMR: Kynetec PetTrak – Pets Since Launch December 2022, Zoetis Inc.
- Data on file, APOQUEL/CYTOPOINT Vet Tracker Wave 17, 2022, Zoetis Inc.
- Data on file, APOQUEL/CYTOPOINT Pet Owner Tracker Wave 11, 2022, Zoetis Inc.
- Olivry T, DeBoer DJ, Favrot C, et al; for the International Committee on Allergic Diseases of Animals. Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA). BMC Vet Med Assoc. 2015;241(2):194-207.
- Cosgrove SB, Wren JA, Cleaver DM, et al. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Vet Dermatol. 2013;24(5):479- e114. doi: 10.1111/vde.12047
- Cosgrove SB, Cleaver DM, King VL, et al. Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life. Vet Dermatol. 2015;26:171-179.
- Gonzales AJ, Bowman JW, Fici G, et al. Oclacitinib (APOQUEL®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy. J Vet Pharmacol Ther. 2014;37(4):317-324.
APQ-00679R11
